ArGEN-X

ArGEN-X

ArGEN-X

arGENX is a clinicalstage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases.
Founded
2008
Raised
$33.3M
Follow us
Alexa global traffic share
Latest funding
€30,000,000
Post-IPO equity - 2016
MPM Capital Dafna Capital Management Burrage Capital +1
€32
Venture capital (Series B) - 2011
Omnes Capital
Team Size
10+
Employees
PE HUB

VC-backed Argenx hikes up IPO offering to five million shares

€30,000,000 Post-IPO equity
BioPortfolio

argenx successfully closes €30 million private placement

Health Privacy